Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Mar 12, 2013

Top 20 Biopharma R&D Spenders

Which companies have the deepest pockets for research and development?

Top 20 Biopharma R&D Spenders

These firms opened up their wallets in hopes that the old adage is true: you’ve got to spend money to make money. [Maxim_Kazmin - Fotolia.com]

  • Click Image To Enlarge +
    Top 20 Biopharma R&D Spenders

    When it comes to research and development, you've got to give to get. Whether or not you actually get what you pay for is a matter of debate, but generally the biopharma companies that spend the most on R&D will be the ones to watch the most closely in the future for new developments. You've seen the top 10 pharma firms and the top 25 biotech companies: are any of the companies on those lists among the biggest R&D spenders?

    To the right is GEN's list of top 20 biopharmas ranked by their R&D spending for 2012. Listings include R&D spending for 2012 and 2011, the percentage difference between the two years, the percentage of sales for both years, and 2008 R&D spending and percentage of sales. Figures were disclosed by the companies in annual reports, and quarterly results press releases. Where applicable, figures were converted to U.S. dollars from other currencies.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »